XML 51 R23.htm IDEA: XBRL DOCUMENT
v3.22.1

Trade and Other Payables | 12 Months Ended
--- | ---
Dec. 31, 2021
Disclosure Of Trade And Other Payables [Abstract] |
Trade and Other Payables | TRADE AND OTHER PAYABLES Trade and other payables consisted of the following:
| Trade and other payables - Total |  | As of
| (in € thousands) |  | 2019/12/31 |  | 2020/12/31 |  | 2021/12/31
| Trade payables (*) |  | 32,753 |  |  | 20,337 |  |  | 12,304 |
| Social security costs payables |  | 3,598 |  |  | 4,477 |  |  | 4,087 |
| VAT payables |  | 2 |  |  | 314 |  |  | 23,725 |
| Taxes payables |  | 487 |  |  | 319 |  |  | 744 |
| Other payables |  | 527 |  |  | 569 |  |  | 579 |
| TOTAL |  | 37,368 |  |  | 26,015 |  |  | 41,438 |
| Trade and other payables - Current |  | As of
| (in € thousands) |  | 2019/12/31 |  | 2020/12/31 |  | 2021/12/31
| Trade payables |  | 32,753 |  |  | 20,337 |  |  | 12,304 |
| Social security costs payables |  | 3,598 |  |  | 4,477 |  |  | 4,087 |
| VAT payables |  | 2 |  |  | 314 |  |  | 23,725 |
| Taxes payables |  | 487 |  |  | 319 |  |  | 744 |
| Other payables |  | 76 |  |  | 118 |  |  | 128 |
| TOTAL |  | 36,917 |  |  | 25,564 |  |  | 40,988 |
| Trade and other payables - Non current |  | As of
| (in € thousands) |  | 2019/12/31 |  | 2020/12/31 |  | 2021/12/31
| Trade payables |  | — |  |  | — |  |  | — |
| Social security costs payables |  | — |  |  | — |  |  | — |
| VAT payables |  | — |  |  | — |  |  | — |
| Taxes payables |  | — |  |  | — |  |  | — |
| Other payables |  | 450 |  |  | 450 |  |  | 450 |
| TOTAL |  | 450 |  |  | 450 |  |  | 450 |
| (*) Of which : Accrued expenses |  | 18,682 |  |  | 13,809 |  |  | 6,201 |
At December 31, 2021, trade payables amounted to €12,304 (€20,337 at December 31, 2020). This change is due to the reduction in operating expenses. Trade payables include a significant portion of accrued expenses (€6,201 and €13,809 at December 31, 2021 and 2020 respectively), relating to yet unbilled amounts from the clinical trial sites via the Clinical Research Organizations (CROs) in charge of the Company's clinical trials. The timeframe in which those invoices will be received by the Company is unknown and may be spread out over a long period after the services have been performed. While at December 31, 2020, accrued expenses related to RESOLVE-IT, amounted to $9.6 million (€7.8 million) and €2.3 million, i.e. a total of €10.1 million, at December 31, 2021, they amounted to $0.9 million (€0.8 million) and €0.4 million, i.e. a total of €1.2 million). This reduction reflects the increase in RESOLVE-IT clinical trial sites closures following the decision taken mid-2020 to discontinue this study. The VAT debt amounted to €23,725 at December 31, 2021 (€314 at December 31, 2020). This increase is related to the VAT amount collected on the upfront payment received from Ipsen in December 2021.

X
- Definition Disclosure of trade and other payables abstract. + References No definition available. + Details
Name: | gnft_DisclosureOfTradeAndOtherPayablesAbstract
Namespace Prefix: | gnft_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of trade and other payables. [Refer: Trade and other payables] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2021-01-01 -Paragraph 10 -Subparagraph e -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_10_e&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration